Survival outcomes in men with a positive family history of prostate cancer: a registry based study
Affiliations
- PMID: 32948129
- DOI: 10.1186/s12885-020-07174-9
Abstract
Background: To investigate the correlation between family history of prostate cancer (PCa) and survival (overall and cancer specific) in patients undergoing treatment for PCa.
Methods: ine thousand four hundred fifty-nine patients with PCa were extracted from the South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC) database. Diagnosis occurred after 1998 and treatment before 2014. Cox proportional-hazards modeling was used to assess the effect of family history on overall survival after adjustment for confounders (age at diagnosis, NCCN risk category and year of treatment), and with stratification by primary treatment group. Competing risks regression modelling was used to assess PCa specific mortality.
Results: Men with a positive family history of PCa appear to have a lower Gleason score at the time of diagnosis (50% with Gleason < 7, compared to 39% in those without family history) and be diagnosed at a lower age (64 vs 69). Men with a positive family history of PCa appear to have better overall survival outcomes (p < 0.001, log rank test). In analysis adjusting for age at diagnosis, NCCN risk category and year of treatment, family history remained a significant factor when modelling overall survival (HR 0.72 95% CI 0.55-0.95, p = 0.021). There were no significant differences in treatment subgroups of radical prostatectomy (p = 0.7) and radiotherapy (0.054).
Conclusion: Men with a positive family history of PCa appear to have better overall survival outcomes. This better survival may represent lead time bias and early initiation of PSA screening. Family history of PCa was not associated with different survival outcomes in men who were treated with either radical prostatectomy or radiotherapy.
Keywords: Family history; Genetics; Outcomes; Prostate Cancer; Survival.
Similar articles
- Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL.BJU Int. 2016 Apr;117 Suppl 4:68-75. doi: 10.1111/bju.13411. Epub 2016 Feb 18.PMID: 26890320
- Prostate cancer outcomes for men who present with symptoms at diagnosis.BJU Int. 2017 Jun;119(6):862-871. doi: 10.1111/bju.13622. Epub 2016 Sep 3.PMID: 27489140
- Effect on survival of local treatment in patients with low prostate-specific antigen, high Gleason score prostate cancer: a population-based propensity score-matched analysis.Ann Palliat Med. 2020 Jul;9(4):1708-1717. doi: 10.21037/apm-19-414. Epub 2020 May 30.PMID: 32527134
- Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review.Eur Urol. 2019 Jun;75(6):967-987. doi: 10.1016/j.eururo.2018.10.011. Epub 2018 Oct 17.PMID: 30342843 Review.
- Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May. Report No.: 17-05229-EF-1.PMID: 30085502 Free Books & Documents. Review.
No hay comentarios:
Publicar un comentario